Please try another search
For the three months ended 31 March 2016, Alexza Pharmaceuticals, Inc. revenues increased 2% to $720K. Net loss increased from $404K to $3.4M. Revenues reflect Collaboration revenue increase of 17% to $720K. Higher net loss reflects Change in fair value of contingent consi decrease of 99% to $200K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.02 to -$0.16.
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Revenue | 0.72 | 0.67 | 1.77 | 1.88 |
Gross Profit | -0.23 | -6.5 | -1.9 | -2.26 |
Operating Income | -1.6 | -9.98 | -7.6 | -9.44 |
Net Income | -3.36 | -3.02 | -5.44 | -12.45 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Assets | 10.58 | 14.73 | 26.22 | 32.63 |
Total Liabilities | 84.92 | 86.39 | 95.07 | 96.54 |
Total Equity | -74.33 | -71.66 | -68.85 | -63.91 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -4.25 | -31.88 | -28.34 | -20.88 |
Cash From Investing Activities | 0 | 19.45 | 19.45 | 15.95 |
Cash From Financing Activities | 1 | 4.99 | 4.98 | 1.92 |
Net Change in Cash | -3.25 | -7.45 | -3.91 | -3.01 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review